These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27138868)

  • 21. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy.
    Desai K; Misra P; Kher S; Shah N
    Exp Hematol Oncol; 2018; 7():22. PubMed ID: 30202638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First Pegfilgrastim Biosimilar Approved.
    Aschenbrenner DS
    Am J Nurs; 2018 Oct; 118(10):19-20. PubMed ID: 30260881
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
    Finck B; Tang H; Civoli F; Hodge J; O'Kelly H; Vexler V
    Adv Ther; 2020 Oct; 37(10):4291-4307. PubMed ID: 32789809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
    Yao HM; Jones SR; Morales S; Moosavi S; Zhang J; Freyman A; Ottery FD
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1033-1048. PubMed ID: 34618197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development.
    Li F; Sun Q; Du S; Florian J; Wang Y; Huang SM; Zineh I; Wang YC
    Clin Pharmacol Ther; 2023 Jan; 113(1):62-70. PubMed ID: 36000498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.
    Brokx S; Scrocchi L; Shah N; Dowd J
    Biologicals; 2017 Jul; 48():28-38. PubMed ID: 28619479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
    Wynne C; Schwabe C; Vincent E; Schueler A; Ryding J; Ullmann M; Ghori V; Kanceva R; Stahl M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00578. PubMed ID: 32333641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.
    Choi C; Yoo BW; Kim CO; Hong T; Jin BH; Seo KS; Jang JY; Park MS
    Drug Des Devel Ther; 2018; 12():2381-2387. PubMed ID: 30122896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).
    Agarwala SS; Nagl U; Guo X; Bellon A; Heyn J; Dimova-Dobreva M; Shen YM; Schaffar G; Humphrey M; Mathieson N; Koptelova N; Gattu S
    Curr Med Res Opin; 2022 Jun; 38(6):999-1009. PubMed ID: 35392751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
    Brekkan A; Lopez-Lazaro L; Yngman G; Plan EL; Acharya C; Hooker AC; Kankanwadi S; Karlsson MO
    AAPS J; 2018 Aug; 20(5):91. PubMed ID: 30112626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
    Harbeck N; Wang J; Otto GP; Gattu S; Krendyukov A
    Future Oncol; 2019 Apr; 15(12):1313-1322. PubMed ID: 30834780
    [No Abstract]   [Full Text] [Related]  

  • 40. RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.
    Sántha D; Illés A; Aradi I; Horvát-Karajz K; Kahán Z
    Future Oncol; 2019 Jun; 15(18):2083-2092. PubMed ID: 31210542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.